Warning: count(): Parameter must be an array or an object that implements Countable in /home/logicben/public_html/drugtrialsformoney.com/wp-content/plugins/redux-framework/redux-core/inc/classes/class-redux-output.php on line 391

Gastroenterology

  • Home
  • Gastroenterology
Headache Relief Shampoo Voted #1 Best New Product in 2019

Dr. D’s Medicated Headache Relief Shampoo is now available. This medicated shampoo will help alleviate headaches simply by soaking it on your head. Finding relief from minor to severe headaches shouldn’t always involve reaching for a bottle of pills. Dr. D is here to give you another option. Our proprietary formula will leave your head feeling better.

BUY NOW! http://headachereliefshampoo.com/product/headache-relief-shampoo/

January 1, 2019 / by / in
Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer
Conditions:   Clinical Stage III Gastric Cancer AJCC v8;   Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8;   Clinical Stage IV Gastric Cancer AJCC v8;   Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8;   Clinical Stage IVA Gastric Cancer AJCC v8;   Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8;   Clinical Stage IVB Gastric Cancer AJCC v8;   Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8;   Metastatic Gastric Adenocarcinoma;   Metastatic Gastroesophageal Junction Adenocarcinoma;   Pathologic Stage III Gastric Cancer AJCC v8;   Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IIIA Gastric Cancer AJCC v8;   Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IIIB Gastric Cancer AJCC v8;   Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IIIC Gastric Cancer AJCC v8;   Pathologic Stage IV Gastric Cancer AJCC v8;   Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8;   Postneoadjuvant Therapy Stage III Gastric Cancer AJCC v8;   Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8;   Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8;   Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8;   Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8;   Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8;   Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8;   Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8;   Unresectable Gastric Adenocarcinoma;   Unresectable Gastroesophageal Junction Adenocarcinoma
Interventions:   Drug: Berzosertib;   Drug: Irinotecan
Sponsor:   National Cancer Institute (NCI)
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

September 23, 2020 / by / in
First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours
Conditions:   Clear Cell Renal Cell Cancer;   Non-Small-Cell Lung Cancer;   Triple Negative Breast Neoplasms;   Squamous Cell Cancer of Head and Neck;   Small Cell Lung Cancer;   Gastric Cancer;   Melanoma;   Cervical Cancer;   Advanced Solid Tumours
Interventions:   Drug: AZD8701;   Biological: Durvalumab
Sponsor:   AstraZeneca
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

September 23, 2020 / by / in
Study of ECHELON Endopath(TM) Staple Line Reinforcement
Conditions:   Gastric Procedures;   Lung Resection Procedures
Intervention:   Device: Staple Line Reinforcement
Sponsor:   Ethicon Endo-Surgery
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

September 17, 2020 / by / in
Pediatric Acute Gastrointestinal Bleeding Registry
Conditions:   Upper Gastrointestinal Bleeding;   Gastro Intestinal Bleeding
Intervention:   Other: This is an obsevational cohort study
Sponsors:   Boston Children’s Hospital;   Baylor College of Medicine;   Children’s Medical Center Dallas;   University of Massachusetts, Worcester;   Children’s Hospital of Philadelphia;   Ann & Robert H Lurie Children’s Hospital of Chicago
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

September 17, 2020 / by / in
A Study of RGX-202-01 as a Single Agent and as Combination Therapy in Patients With Advanced Gastrointestinal Malignancies
Conditions:   Gastrointestinal Cancer;   Gastrointestinal Neoplasms;   Colorectal Cancer;   Colorectal Neoplasms;   Colorectal Carcinoma;   Gastric Cancer;   Gastric Neoplasm;   Pancreatic Cancer;   Pancreatic Neoplasm
Interventions:   Drug: RGX-202-01;   Drug: FOLFIRI;   Drug: Bevacizumab
Sponsor:   Rgenix, Inc.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

September 12, 2020 / by / in
A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants With Symptomatic Diabetic or Idiopathic Gastroparesis
Conditions:   Diabetic Gastroparesis;   Idiopathic Gastroparesis
Intervention:   Drug: NG101
Sponsor:   Neurogastrx, Inc.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

September 4, 2020 / by / in
Use of Intrapyloric Botulinum Injections in Children
Conditions:   Vomiting;   Feeding Disorders;   Gastroparesis
Intervention:  
Sponsor:   Boston Children’s Hospital
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

September 3, 2020 / by / in
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Colorectal, or Gastric Cancer
Conditions:   Clinical Stage IV Gastric Cancer AJCC v8;   Clinical Stage IVA Gastric Cancer AJCC v8;   Clinical Stage IVB Gastric Cancer AJCC v8;   Malignant Uterine Neoplasm;   Metastatic Colorectal Carcinoma;   Metastatic Gastric Carcinoma;   Metastatic Malignant Neoplasm in the Peritoneum;   Metastatic Ovarian Carcinoma;   Pathologic Stage IV Gastric Cancer AJCC v8;   Peritoneal Carcinomatosis;   Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8;   Stage IV Colorectal Cancer AJCC v8;   Stage IV Ovarian Cancer AJCC v8;   Stage IV Uterine Corpus Cancer AJCC v8;   Stage IVA Colorectal Cancer AJCC v8;   Stage IVA Ovarian Cancer AJCC v8;   Stage IVA Uterine Corpus Cancer AJCC v8;   Stage IVB Colorectal Cancer AJCC v8;   Stage IVB Ovarian Cancer AJCC v8;   Stage IVB Uterine Corpus Cancer AJCC v8;   Stage IVC Colorectal Cancer AJCC v8;   Stage IIIA Ovarian Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIA Endometrial Cancer;   Stage IIIB Endometrial Cancer;   Stage IIIC Endometrial Cancer
Interventions:   Drug: Cisplatin;   Drug: Doxorubicin;   Drug: Fluorouracil;   Procedure: Intraperitoneal Chemotherapy;   Drug: Leucovorin;   Drug: Oxaliplatin;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Device: Nebulizer with High-Pressure Injector
Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

September 2, 2020 / by / in
Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1.
Conditions:   Pancreatic Ductal Adenocarcinoma;   Colorectal Cancer;   Gastric Cancer;   Squamous Cell Carcinoma of the Head and Neck;   Bone Cancer;   Advanced Cancer;   Recurrent Disease;   Metastatic Tumours
Intervention:   Drug: 177Lu-3BP-227 (also called 177Lu-IPN01087)
Sponsor:   Ipsen
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

September 1, 2020 / by / in
Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers
Condition:   HER2-expressing Cancers
Interventions:   Drug: ZW25 (Zanidatamab);   Combination Product: Paclitaxel;   Combination Product: Capecitabine;   Combination Product: Vinorelbine
Sponsor:   Zymeworks Inc.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

August 28, 2020 / by / in